专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09581595B2 Compositions and methods for determining whether a subject would benefit from co-receptor inhibitor therapy 有权
标题翻译：用于确定受试者是否将受益于共受体抑制剂治疗的组合物和方法
公开(公告)号：US09581595B2
公开(公告)日：2017-02-28
申请号：US12527863
申请日：2008-02-26
申请人： Wei Huang , Signe Fransen , Christos Petropoulos , Jonathan Toma , Jeannette Whitcomb
发明人： Wei Huang , Signe Fransen , Christos Petropoulos , Jonathan Toma , Jeannette Whitcomb
IPC分类号： G01N33/00 , G01N33/569
CPC分类号： C12Q1/703 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G01N33/56988 , G01N2333/16 , G01N2333/162 , G01N2800/52
摘要： The present invention provides methods and compositions for determining whether a subject would benefit from co-receptor inhibitor therapy. In certain aspects, the methods can be used to determine whether a subject infected with a dual-mixed tropic population of HIV would benefit from CCCR5-inhibitor therapy or CXCR4-inhibitor therapy, the methods comprising determining whether the HIV population is a homogeneous or heterogeneous population of HIV, wherein the nature of the homogenous or heterogenous population of HIV indicates whether the patient would benefit from co-receptor inhibitor therapy.
摘要翻译：本发明提供了用于确定受试者是否将受益于共受体抑制剂治疗的方法和组合物。在某些方面，该方法可用于确定受艾滋病双重混合热带人群感染的受试者是否将受益于CCCR5抑制剂治疗或CXCR4抑制剂治疗，所述方法包括确定HIV群体是否是均质或异质性艾滋病毒的人群，其中艾滋病的同源或异质群体的性质表明患者是否可以从共同受体抑制剂治疗中受益。

2. 发明申请

US20060183110A1 METHODS OF EVALUATING CELL SURFACE RECEPTOR BINDING OF A PATIENT DERIVED POPULATION OF VIRAL ENVELOPE PROTEIN CONSTRUCTS 有权
标题翻译：评估病毒传播病毒人群蛋白质构建体细胞表面受体结合的方法
公开(公告)号：US20060183110A1
公开(公告)日：2006-08-17
申请号：US11233461
申请日：2005-09-21
申请人： Christos Petropoulos , Neil Parkin , Jeannette Whitcomb , Wei Huang
发明人： Christos Petropoulos , Neil Parkin , Jeannette Whitcomb , Wei Huang
IPC分类号： C12Q1/70
CPC分类号： C12Q1/70 , C12Q1/6897 , C12Q1/703 , G01N33/5091 , G01N33/56983
摘要： The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which, lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.
摘要翻译：本发明提供了一种用于鉴定化合物是否抑制病毒进入细胞的方法，其包括：（a）从感染病毒的患者获得编码病毒包膜蛋白的核酸; （b）共转染入第一细胞（i）步骤（a）的核酸，和（ii）缺乏编码包膜蛋白的核酸的病毒表达载体，其包含指示核酸，其产生使得第一细胞产生包含由患者获得的核酸编码的包膜蛋白的病毒颗粒; （c）在化合物存在下使步骤（b）中产生的病毒颗粒与第二细胞接触，其中第二细胞表达病毒结合的细胞表面受体; （d）测量由第二细胞产生的信号量以确定病毒颗粒的感染性; 和（e）将步骤（d）中测量的信号量与在不存在化合物时产生的信号量进行比较，其中在化合物存在下测量的信号量减少表明化合物抑制病毒进入进入第二个细胞。

3. 发明申请

US20050214743A1 Compositions and methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays 审中-公开
标题翻译：用重组病毒测定法评估病毒受体/辅助受体使用的组合物和方法以及病毒进入抑制剂
公开(公告)号：US20050214743A1
公开(公告)日：2005-09-29
申请号：US10504921
申请日：2003-02-14
申请人： Douglas Richman , Mary Wrin , Susan Little , Christos Petropoulos , Neil Parkin , Jeannette Whitcomb , Wei Huang
发明人： Douglas Richman , Mary Wrin , Susan Little , Christos Petropoulos , Neil Parkin , Jeannette Whitcomb , Wei Huang
IPC分类号： C12N15/86 , C12Q1/68 , C12Q1/70
CPC分类号： G01N33/56988 , C07K14/005 , C07K14/16 , C07K14/162 , C07K16/08 , C07K16/10 , C12Q1/6897 , C12Q1/703 , G01N33/5044 , G01N33/5091 , G01N33/56983 , G01N2333/16
摘要： The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic add of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.
摘要翻译：本发明提供了鉴定化合物是否抑制病毒进入细胞的方法，该方法包括：（a）从病毒感染的患者获得编码病毒包膜蛋白的核酸; （b）共转染入第一细胞（i）步骤（a）的核酸添加，和（ii）缺乏编码包膜蛋白的核酸的病毒表达载体，其包含指示核酸，其产生使得第一细胞产生包含由患者获得的核酸编码的包膜蛋白的病毒颗粒; （c）在化合物存在下使步骤（b）中产生的病毒颗粒与第二细胞接触，其中第二细胞表达病毒结合的细胞表面受体; （d）测量由第二细胞产生的信号量以确定病毒颗粒的感染性; 和（e）将步骤（d）中测量的信号量与在不存在化合物时产生的信号量进行比较，其中在化合物存在下测量的信号量减少表明化合物抑制病毒进入进入第二个细胞。

4. 发明申请

US20060160185A1 METHODS OF EVALUATING VIRAL ENTRY INHIBITORS USING PATIENT DERIVED ENVELOPE PROTEIN CONSTRUCTS 有权
标题翻译：使用患者衍生的包膜蛋白质构建体评估病毒入侵抑制剂的方法
公开(公告)号：US20060160185A1
公开(公告)日：2006-07-20
申请号：US11323189
申请日：2005-12-29
申请人： Christos Petropoulos , Neil Parkin , Jeannette Whitcomb , Wei Huang
发明人： Christos Petropoulos , Neil Parkin , Jeannette Whitcomb , Wei Huang
IPC分类号： C12Q1/68 , C12P21/06
CPC分类号： C12Q1/70 , C12Q1/6897 , C12Q1/703 , G01N33/5091 , G01N33/56983
摘要： The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.
摘要翻译：本发明提供了一种用于鉴定化合物是否抑制病毒进入细胞的方法，其包括：（a）从感染病毒的患者获得编码病毒包膜蛋白的核酸; （b）共转染入第一细胞（i）步骤（a）的核酸，和（ii）缺乏编码包膜蛋白的核酸的病毒表达载体，其包含指示核酸，其产生使得第一细胞产生包含由患者获得的核酸编码的包膜蛋白的病毒颗粒; （c）在化合物存在下使步骤（b）中产生的病毒颗粒与第二细胞接触，其中第二细胞表达病毒结合的细胞表面受体; （d）测量由第二细胞产生的信号量以确定病毒颗粒的感染性; 和（e）将步骤（d）中测量的信号量与在不存在化合物时产生的信号量进行比较，其中在化合物存在下测量的信号量减少表明化合物抑制病毒进入进入第二个细胞。

5. 发明申请

US20100167266A1 Compositions and Methods for Determining Whether a Subject Would Benefit from Co-Receptor Inhibitor Therapy 有权
标题翻译：用于确定受试者是否受益于共受体抑制剂治疗的组合物和方法
公开(公告)号：US20100167266A1
公开(公告)日：2010-07-01
申请号：US12527863
申请日：2008-02-26
申请人： Wei Huang , Signe Franson , Christos J. Petropoulos , Jonathan Toma , Jeannette Whitcomb
发明人： Wei Huang , Signe Franson , Christos J. Petropoulos , Jonathan Toma , Jeannette Whitcomb
IPC分类号： C12Q1/70
CPC分类号： C12Q1/703 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G01N33/56988 , G01N2333/16 , G01N2333/162 , G01N2800/52
摘要： The present invention provides methods and compositions for determining whether a subject would benefit from co-receptor inhibitor therapy. In certain aspects, the methods can be used to determine whether a subject infected with a dual-mixed tropic population of HIV would benefit from CCCR5-inhibitor therapy or CXCR4-inhibitor therapy, the methods comprising determining whether the HIV population is a homogeneous or heterogeneous population of HIV, wherein the nature of the homogenous or heterogenous population of HIV indicates whether the patient would benefit from co-receptor inhibitor therapy.
摘要翻译：本发明提供了用于确定受试者是否将受益于共受体抑制剂治疗的方法和组合物。在某些方面，该方法可用于确定受艾滋病双重混合热带人群感染的受试者是否将受益于CCCR5抑制剂治疗或CXCR4抑制剂治疗，所述方法包括确定HIV群体是否是均质或异质性艾滋病毒的人群，其中艾滋病的同源或异质群体的性质表明患者是否可以从共同受体抑制剂治疗中受益。

6. 发明授权

US09175355B2 Methods for determining the presence of antibodies blocking viral infection 有权
标题翻译：测定阻断病毒感染的抗体存在的方法
公开(公告)号：US09175355B2
公开(公告)日：2015-11-03
申请号：US12635539
申请日：2009-12-10
申请人： Douglas Richman , Mary T. Wrin , Susan Little , Christos J. Petropoulos , Neil T. Parkin , Jeannette Whitcomb , Wei Huang
发明人： Douglas Richman , Mary T. Wrin , Susan Little , Christos J. Petropoulos , Neil T. Parkin , Jeannette Whitcomb , Wei Huang
IPC分类号： C12Q1/70 , C12Q1/68 , G01N33/50 , G01N33/569 , C07K14/16 , C07K16/08 , C07K14/005 , C07K16/10
CPC分类号： G01N33/56988 , C07K14/005 , C07K14/16 , C07K14/162 , C07K16/08 , C07K16/10 , C12Q1/6897 , C12Q1/703 , G01N33/5044 , G01N33/5091 , G01N33/56983 , G01N2333/16
摘要： The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.
摘要翻译：本发明提供了鉴定化合物是否抑制病毒进入细胞的方法，该方法包括：（a）从病毒感染的患者获得编码病毒包膜蛋白的核酸; （b）共转染入第一细胞（i）步骤（a）的核酸，和（ii）缺乏编码包膜蛋白的核酸的病毒表达载体，其包含指示核酸，其产生使得第一细胞产生包含由患者获得的核酸编码的包膜蛋白的病毒颗粒; （c）在化合物存在下使步骤（b）中产生的病毒颗粒与第二细胞接触，其中第二细胞表达病毒结合的细胞表面受体; （d）测量由第二细胞产生的信号量以确定病毒颗粒的感染性; 和（e）将步骤（d）中测量的信号量与在不存在化合物时产生的信号量进行比较，其中在化合物存在下测量的信号量减少表明化合物抑制病毒进入进入第二个细胞。

7. 发明授权

US07037644B1 Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS 失效
公开(公告)号：US07037644B1
公开(公告)日：2006-05-02
申请号：US09320299
申请日：1999-05-26
申请人： Jeannette Whitcomb
发明人： Jeannette Whitcomb
IPC分类号： C12Q1/70
CPC分类号： C12Q1/703
摘要： This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) and further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy, particularly non-nucleoside reverse transcriptase inhibitor therapy using phenotypic susceptibility assays or genotypic assays.

8. 发明申请

US20080293038A1 Method for Determining Resistance of Hiv to Nucleoside Reverse Transcriptase Inhibitor Treatment 审中-公开
标题翻译：用于确定核苷逆转录酶抑制剂治疗抗性的方法
公开(公告)号：US20080293038A1
公开(公告)日：2008-11-27
申请号：US11915307
申请日：2006-05-25
申请人： Neil T. Parkin , Colombe Chappey , Jeannette Whitcomb
发明人： Neil T. Parkin , Colombe Chappey , Jeannette Whitcomb
IPC分类号： C12Q1/70
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention provides methods and devices for predicting whether an HIV-1 is resistant to an antiviral drug based on the HIV-1's genotype. In one aspect, the invention provides methods comprising determining whether a mutation or combination of mutations associated with NRTI resistance are present, as disclosed herein, thereby assessing the effectiveness of FTC therapy in the HIV-infected subject. Computer implemented methods comprising determining HIV-1 resistance are provided.
摘要翻译：本发明提供了用于预测HIV-1是否对基于HIV-1的基因型的抗病毒药具有抗性的方法和装置。一方面，本发明提供了如本文所公开的确定是否存在与NRTI抗性相关的突变或突变的组合的方法，从而评估FTC治疗在HIV感染的受试者中的有效性。提供了确定HIV-1抗性的计算机实施方法。

9. 发明申请

US20050059033A1 Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS 失效
标题翻译：用于监测非核苷逆转录酶抑制剂抗逆转录病毒治疗的手段和方法，并指导治疗艾滋病毒/艾滋病的治疗决定
公开(公告)号：US20050059033A1
公开(公告)日：2005-03-17
申请号：US10758683
申请日：2004-01-14
申请人： Jeannette Whitcomb
发明人： Jeannette Whitcomb
IPC分类号： C12Q1/68 , C12Q1/70 , C07H21/04
CPC分类号： C12Q1/703
摘要： This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) and further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy, particularly non-nucleoside reverse transcriptase inhibitor therapy using phenotypic susceptibility assays or genotypic assays.
摘要翻译：本发明涉及用于鉴定用于治疗人类免疫缺陷病毒（HIV）感染和获得性免疫缺陷综合征（AIDS）的有效药物方案的抗病毒药物敏感性和抗性测试，并且还涉及监测临床进展的手段和方法 HIV感染及其对抗逆转录病毒治疗的反应，特别是使用表型易感性测定或基因型测定的非核苷逆转录酶抑制剂治疗。

10. 发明授权

US06653081B2 Methods for monitoring antiretroviral therapy and guiding therapeutic decision in the treatment of HIV/AIDS 失效
标题翻译：监测抗逆转录病毒治疗方法和指导治疗艾滋病毒/艾滋病的治疗决定
公开(公告)号：US06653081B2
公开(公告)日：2003-11-25
申请号：US09881033
申请日：2001-06-12
申请人： Jeannette Whitcomb
发明人： Jeannette Whitcomb
IPC分类号： C12Q168
CPC分类号： C12Q1/703
摘要： This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) and further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy, particularly nucleoside reverse transcriptase inhibitor therapy using phenotypic susceptibility assays or genotypic assays.
摘要翻译：本发明涉及用于鉴定用于治疗人类免疫缺陷病毒（HIV）感染和获得性免疫缺陷综合征（AIDS）的有效药物方案的抗病毒药物敏感性和抗性测试，并且还涉及监测临床进展的手段和方法艾滋病毒感染及其对抗逆转录病毒治疗的反应，特别是使用表型易感性测定或基因型测定的核苷逆转录酶抑制剂治疗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式